Aleta Biotherapeutics focuses on transforming cellular therapeutics to allow a broader spectrum of cancer indications to be targeted.
Aleta Biotherapeutics has raised $13.7M in total funding. The most recent round was Series A. The last funding was announced in July 2021.
Aleta Biotherapeutics's investors include Advent Life Sciences, Viva BioInnovator.
Aleta Biotherapeutics is headquartered in Natick, United States.
Aleta Biotherapeutics focuses on transforming cellular therapeutics to allow a broader spectrum of cancer indications to be targeted.
Aleta Biotherapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Aleta Biotherapeutics — Funding & Investors." VCBacked, July 16, 2021, https://www.vcbacked.co/company/aleta-biotherapeutics. Accessed August 14, 2026.
VCBacked. (2021). Aleta Biotherapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/aleta-biotherapeutics
{{cite web |title=Aleta Biotherapeutics — Funding & Investors |url=https://www.vcbacked.co/company/aleta-biotherapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated